Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;23(7):781-784.
doi: 10.1016/S1473-3099(23)00289-X. Epub 2023 Jun 5.

Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection

Edward J Carr  1 , Mary Y Wu  2 , Joshua Gahir  3 , Ruth Harvey  4 , Hermaleigh Townsley  3 , Chris Bailey  3 , Ashley S Fowler  5 , Giulia Dowgier  6 , Agnieszka Hobbs  6 , Lou Herman  6 , Martina Ragno  6 , Murad Miah  5 , Phillip Bawumia  5 , Callie Smith  5 , Mauro Miranda  5 , Harriet V Mears  5 , Lorin Adams  4 , Emine Haptipoglu  3 , Nicola O'Reilly  5 , Scott Warchal  5 , Chelsea Sawyer  5 , Karen Ambrose  5 , Gavin Kelly  5 , Rupert Beale  1 , Padmasayee Papineni  7 , Tumena Corrah  7 , Richard Gilson  8 , Steve Gamblin  5 , George Kassiotis  9 , Vincenzo Libri  10 , Bryan Williams  10 , Charles Swanton  1 , Sonia Gandhi  1 , David Lv Bauer  5 , Emma C Wall  11 ; Crick COVID Serology Consortium
Affiliations

Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection

Edward J Carr et al. Lancet Infect Dis. 2023 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

All authors declare they have no competing interests. All data (anonymised) and full R code to produce all figures and statistical analysis presented in this Correspondence are available online on Github: https://github.com/davidlvb/Crick-UCLH-Legacy-XBB-2023-03. This study was sponsored by University College London Hospitals. This study was undertaken at University College London Hospitals and University College London, which received a proportion of funding from the National Institute for Health Research University College London Hospitals Biomedical Research Centre and Clinical Research Facility. ECW, VL, and BW are supported by the Biomedical Research Centre funding scheme. This study was supported jointly by the Biomedical Research Centre and core funding from the Francis Crick Institute, which receives its funding from Cancer Research UK, the UK Medical Research Council, and the Wellcome Trust. DLVB and RB are additionally supported by the Genotype-to-Phenotype (G2P) National Virology Consortium via UK Research and Innovation and the UK Medical Research Council. The funders of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data and the final responsibility to submit for publication.

Figures

Figure
Figure
Bivalent vaccination induces neutralising antibodies against omicron lineage variants in healthy adults (A) Distribution of live-virus microneutralisation titres against SARS-CoV-2 ancestral, delta, or omicron subvariants across the cohort are shown as the log of the IC50 for serum samples drawn before or after bivalent mRNA vaccination. (B) Live-virus microneutralisation titres against SARS-CoV-2 ancestral, delta, or omicron subvariants for serum samples drawn before or after bivalent mRNA vaccination, stratified by previous seroconversion to SARS-CoV-2 nucleoprotein (sero-negative or positive indicated by anti-N negative and anti-N positive, respectively). The numbers of serum samples included in each group are indicated on the ancestral plot. p values shown are from unpaired, two-tailed Wilcoxon tests, or McNemar's χ2 tests if the median of one group was more or less than the quantitative range of the assay (40–2560). The fold-change induction of neutralising antibody titres and 95% CIs are shown where both group medians are within the quantitative range. IC50=50% inhibitory concentration.
See this image and copyright information in PMC

References

    1. Tan CY, Chiew CJ, Pang D, et al. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study. Lancet Infect Dis. 2023 doi: 10.1016/S1473-3099(23)00060-9. published online March 13. - DOI - PMC - PubMed
    1. Goh AXC, Chae S-R, Chiew CJ, et al. Characteristics of the omicron XBB subvariant wave in Singapore. Lancet. 2023;401:1261–1262. - PubMed
    1. Boyton RJ, Altmann DM. Imprinted hybrid immunity against XBB reinfection. Lancet Infect Dis. 2023 doi: 10.1016/S1473-3099(23)00138-X. published online March 13. - DOI - PMC - PubMed
    1. Gov.UK
    2. JCVI advises an autumn COVID-19 vaccine booster. 2023. https://www.gov.uk/government/news/jcvi-advises-an-autumn-covid-19-vacci...
    1. Wu M, Wall EC, Carr EJ, et al. Three-dose vaccination elicits neutralising antibodies against omicron. Lancet. 2022;399:715–717. - PMC - PubMed

Publication types

Supplementary concepts